ROBERTS PHARMACEUTICAL TO MARKET ORTHO’s SUPPRELIN
ROBERTS PHARMACEUTICAL TO MARKET ORTHO's SUPPRELIN under an exclusive worldwide licensing agreement with the Johnson & Johnson subsidiary, Roberts announced April 13. Designated as an orphan drug, Supprelin (histrelin acetate) was approved by FDA in December for the treatment of central precocious puberty, a disorder that affects an estimated 6,000 children in the U.S., with 2,000 more diagnosed each year ("The Pink Sheet" Jan. 6, p. 12). Roberts Pharmaceutical plans to launch the drug in the U.S. "in the near future." The Eatontown, New Jersey-based company hopes to subsequently market Supprelin in Canada and the United Kingdom, a Roberts Pharmaceutical spokesman said. Approximately 75 Roberts salespeople will market the product; an additional 25 will be added to the staff when Supprelin is marketed abroad. Supprelin is to be administered once daily via subcutaneous injection of 10 mcg/kg of body weight with the injection site varied daily. While Roberts has been developing Somagard (deslorelin) to treat precocious puberty, the company said that the drug will now "be positioned for prostate cancer and endometriosis."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth